[Castration modalities in prostate cancer: Are they all equal?]. / Modalités de castration dans la prise en charge du cancer de la prostate: sont-elles toutes équivalentes ?
Prog Urol
; 26(5): 319-28, 2016 Apr.
Article
en Fr
| MEDLINE
| ID: mdl-27017327
AIM: The aim of this literature review was to focus on the new highlights regarding oncologic and safety outcomes depending on the type of castration used. MATERIAL: Literature search using various algorithms "prostate cancer", "castration", "agonist", "antagonist", "orchiectomy", "GnRH", "FSH", "androgen deprivation therapy" has been performed in April 2015, through the PubMed and Embase databases. RESULTS: GnRH agonists and antagonists are both currently used in clinical practice. Nevertheless, differences regarding their pharmacologic properties have been highlighted in recent studies, specifically regarding the rapidity, sustainability and depth of the castration, but also the decrease in FSH level. Such differences may have oncological impact on the patient, regarding the disease biological control and the time to progression, and a tolerability impact, especially on the cardiovascular risks. The role of the depth and the sustainability of the castration in one hand, the FSH impact in the other hand, as well as a direct inhibition on extra-pituitary GnRH receptors by antagonist might explain these differences. CONCLUSIONS: Recent studies suggest differences between GnRH agonists and antagonist that could impact the patient clinical outcomes. However, further high level of evidence comparative studies remains warranted.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Prostatectomía
/
Neoplasias de la Próstata
/
Orquiectomía
/
Hormona Liberadora de Gonadotropina
/
Antineoplásicos Hormonales
/
Antagonistas de Andrógenos
Tipo de estudio:
Systematic_reviews
Límite:
Humans
/
Male
Idioma:
Fr
Revista:
Prog Urol
Asunto de la revista:
UROLOGIA
Año:
2016
Tipo del documento:
Article
Pais de publicación:
Francia